JP2001500486A - Ｒａｒアンタゴニストとｒｘｒアゴニストとの治療学的組合せおよびその使用 - Google Patents

Ｒａｒアンタゴニストとｒｘｒアゴニストとの治療学的組合せおよびその使用

Info

Publication number
JP2001500486A
JP2001500486A JP10511906A JP51190698A JP2001500486A JP 2001500486 A JP2001500486 A JP 2001500486A JP 10511906 A JP10511906 A JP 10511906A JP 51190698 A JP51190698 A JP 51190698A JP 2001500486 A JP2001500486 A JP 2001500486A
Authority
JP
Japan
Prior art keywords
cancer
rar
rxr
cell
rarα
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP10511906A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001500486A5 (enExample
Inventor
シャンボン，ピエール
グローネマイヤー，ハインリッヒ
アール． レゼック，ピーター
オストロウスキ，ジャセック
Original Assignee
アンスティテュ ナショナル デゥ ラ サンテ エ デゥ ラ ルシェルシュ メディカル
セントル ナショナル デゥ ラ ルシェルシュ サイエンティフィーク
ユニバーシテ ルイ パストゥール
ブリストール―マイヤーズ スクイブ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アンスティテュ ナショナル デゥ ラ サンテ エ デゥ ラ ルシェルシュ メディカル, セントル ナショナル デゥ ラ ルシェルシュ サイエンティフィーク, ユニバーシテ ルイ パストゥール, ブリストール―マイヤーズ スクイブ カンパニー filed Critical アンスティテュ ナショナル デゥ ラ サンテ エ デゥ ラ ルシェルシュ メディカル
Publication of JP2001500486A publication Critical patent/JP2001500486A/ja
Publication of JP2001500486A5 publication Critical patent/JP2001500486A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Quinoline Compounds (AREA)
JP10511906A 1996-08-28 1997-08-28 Ｒａｒアンタゴニストとｒｘｒアゴニストとの治療学的組合せおよびその使用 Ceased JP2001500486A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2477296P 1996-08-28 1996-08-28
US60/024,772 1996-08-28
PCT/US1997/015155 WO1998008546A2 (en) 1996-08-28 1997-08-28 Therapeutic combinations of rar antagonists and rxr agonists and use thereof

Publications (2)

Publication Number Publication Date
JP2001500486A true JP2001500486A (ja) 2001-01-16
JP2001500486A5 JP2001500486A5 (enExample) 2005-04-07

Family

ID=21822317

Family Applications (1)

Application Number Title Priority Date Filing Date
JP10511906A Ceased JP2001500486A (ja) 1996-08-28 1997-08-28 Ｒａｒアンタゴニストとｒｘｒアゴニストとの治療学的組合せおよびその使用

Country Status (11)

Country Link
US (2) US6130230A (enExample)
EP (1) EP0928200B1 (enExample)
JP (1) JP2001500486A (enExample)
AT (1) ATE236654T1 (enExample)
AU (1) AU731060B2 (enExample)
CA (1) CA2263817A1 (enExample)
DE (1) DE69720745T2 (enExample)
ES (1) ES2196361T3 (enExample)
IL (1) IL128723A0 (enExample)
NO (1) NO990912L (enExample)
WO (1) WO1998008546A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012506998A (ja) * 2008-10-28 2012-03-22 フェネックス ファーマシューティカルス アーゲー オーファン核内受容体ｒａｒ関連オーファン受容体ガンマ（ｎｒ１ｆ３）活性を調節するための新規リガンドの同定方法
JP2019517557A (ja) * 2016-06-10 2019-06-24 アイオー セラピューティクス インコーポレイテッド 癌免疫療法のための受容体選択的レチノイドおよびレキシノイド化合物および免疫調節因子

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL142094A0 (en) 1998-09-29 2002-03-10 Gamida Cell Ltd Methods of controlling proliferation and differentiation of stem and progenitor cells
CA2254429A1 (en) * 1998-11-19 2000-05-19 Tully Michael Underhill Compositions for promoting chondrogenesis
WO2000061233A2 (en) * 1999-04-14 2000-10-19 Allergan Sales, Inc. Methods and compositions for the treatment and prevention of lung disease involving a specific rar-gamma agonist
US6436993B1 (en) * 1999-07-13 2002-08-20 The Salk Institute For Biological Studies Use of RAR antagonists as modulators of hormone mediated processes
CA2402413A1 (en) * 2000-03-14 2001-09-20 The University Of Western Ontario Compositions and methods for affecting osteogenesis
US20020090352A1 (en) * 2000-04-13 2002-07-11 Frederick Geissmann Compositions and methods for use in modulating immune system function
JP2004509608A (ja) 2000-05-26 2004-04-02 ボード　オブ　トラスティーズ　オブ　ザ　ユニヴァースティ　オブ　イリノイ レチノイドにより調節される遺伝子の発現を同定する試薬及び方法
US6713515B2 (en) 2000-09-13 2004-03-30 Bristol Myers Squibb Company Retinoic acid receptor antagonists as promoters of angiogenesis
JP2005500027A (ja) * 2001-06-11 2005-01-06 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ ドーパミン分泌細胞の生存を増加させる方法
IL152904A0 (en) * 2002-01-24 2003-06-24 Gamida Cell Ltd Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
EP1465982A4 (en) 2002-01-25 2006-06-07 Gamida Cell Ltd PROCESS FOR EXPANSION OF STEM AND PRESERVATIVE CELLS AND EXPANDED CELL POPULATIONS THEREWITH OBTAINED
US20040097587A1 (en) * 2002-03-27 2004-05-20 Arbiser Jack L Compositions and methods of treatment of ulcerating diseases, burns, and related conditions
JP4473491B2 (ja) * 2002-05-28 2010-06-02 株式会社資生堂 毛穴縮小剤
US20050054731A1 (en) * 2003-09-08 2005-03-10 Franco Folli Multi-system therapy for diabetes, the metabolic syndrome and obesity
US20050112123A1 (en) * 2003-10-06 2005-05-26 Vaughan Michael R. Methods of treating proteinuria
GB2411115A (en) * 2004-02-19 2005-08-24 Medical Res Council Retinoic acid antagonists for the treatment of oesophageal disorders
WO2006030442A2 (en) 2004-09-16 2006-03-23 Gamida-Cell Ltd. Methods of ex vivo progenitor and stem cell expansion by co-culture with mesenchymal cells
US8846393B2 (en) 2005-11-29 2014-09-30 Gamida-Cell Ltd. Methods of improving stem cell homing and engraftment
EP2329817A1 (en) * 2009-09-04 2011-06-08 Ernst-Moritz-Arndt-Universität Greifswald Retinoic acid receptor antagonists, miR-10a inhibitors and inhibitors of HOXB1 or HOXB3 repressors for treating pancreatic cancer
CN111298120A (zh) 2011-06-24 2020-06-19 格里生物公司 炎性病症的预防和治疗
WO2013121426A1 (en) 2012-02-13 2013-08-22 Gamida-Cell Ltd. Culturing of mesenchymal stem cells
US9567569B2 (en) 2012-07-23 2017-02-14 Gamida Cell Ltd. Methods of culturing and expanding mesenchymal stem cells
US9175266B2 (en) 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity
EP3044216B1 (en) 2013-08-20 2022-02-23 University of Washington through its Center for Commercialization Novel and specific inhibitors of cytochrome p450 26 retinoic acid hydroxylase
WO2017091762A1 (en) 2015-11-25 2017-06-01 Io Therapeutics, Inc. Use of cyp26-resistant rar alpha selective agonists in the treatment of cancer
CA3069672A1 (en) 2017-07-13 2019-01-17 Io Therapeutics, Inc. Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
CA3073953A1 (en) 2017-08-31 2019-03-07 Io Therapeutics, Inc. Rar selective agonists in combination with immune modulators for cancer immunotherapy
US12115140B2 (en) * 2020-07-31 2024-10-15 The Trustees Of Columbia University In The City Of New York Method of treating adenoid cystic carcinoma

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU679899B2 (en) 1991-03-18 1997-07-17 Salk Institute For Biological Studies, The Response element compositions and assays employing same
US5780676A (en) * 1992-04-22 1998-07-14 Ligand Pharmaceuticals Incorporated Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors
US5399586A (en) * 1993-03-11 1995-03-21 Allergan, Inc. Treatment of mammals afflicted with tumors with compounds having RXR retinoid receptor agonist activity
US6030794A (en) * 1993-05-18 2000-02-29 Institut National De La Sante Et De La Recherche Medicale Genetically engineered mice and cell lines containing alterations in the genes encoding retinoic acid receptor and retinoid X receptor proteins
US5702914A (en) * 1994-12-21 1997-12-30 The Salk Institute For Biological Studies Use of reporter genes for retinoid receptor screening assays having novel retinoid-associated response elements
AU4530496A (en) 1995-01-13 1996-07-31 Salk Institute For Biological Studies, The Allosteric control of nuclear hormone receptors
US5747661A (en) * 1995-01-13 1998-05-05 Howard Hughes Medical Institute Retinoid-inducible response elements
US5559248A (en) * 1995-04-05 1996-09-24 Bristol-Myers Squibb Co. Retinoid-like heterocycles
US6025388A (en) * 1995-04-26 2000-02-15 Allergan Sales, Inc. Method for inhibiting gene expression promoted by AP1 protein with RARβ selective retinoids and method for treatment of diseases and conditions with such retinoids
US5906920A (en) 1995-08-29 1999-05-25 The Salk Institute For Biological Studies Methods for the detection of ligands for retinoid X receptors
US6586455B1 (en) 1996-12-31 2003-07-01 The Salk Institute For Biological Studies Treatment of liposarcomas using a combination of thiazolidinediones and retinoid X receptor selective agonists
EP0963199A1 (en) 1996-12-31 1999-12-15 The Salk Institute For Biological Studies Treatment of disease states which result from neoplastic cell proliferation using ppar-gamma activators and compositions useful therefor
US6387673B1 (en) 1997-05-01 2002-05-14 The Salk Institute For Biological Studies Compounds useful for the modulation of processes mediated by nuclear hormone receptors, methods for the identification and use of such compounds

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012506998A (ja) * 2008-10-28 2012-03-22 フェネックス ファーマシューティカルス アーゲー オーファン核内受容体ｒａｒ関連オーファン受容体ガンマ（ｎｒ１ｆ３）活性を調節するための新規リガンドの同定方法
JP2019517557A (ja) * 2016-06-10 2019-06-24 アイオー セラピューティクス インコーポレイテッド 癌免疫療法のための受容体選択的レチノイドおよびレキシノイド化合物および免疫調節因子

Also Published As

Publication number Publication date
US6653322B1 (en) 2003-11-25
NO990912D0 (no) 1999-02-25
DE69720745D1 (de) 2003-05-15
ES2196361T3 (es) 2003-12-16
WO1998008546A2 (en) 1998-03-05
DE69720745T2 (de) 2004-02-26
WO1998008546A3 (en) 1998-04-23
CA2263817A1 (en) 1998-03-05
IL128723A0 (en) 2000-01-31
EP0928200A2 (en) 1999-07-14
AU731060B2 (en) 2001-03-22
NO990912L (no) 1999-04-27
US6130230A (en) 2000-10-10
AU4167497A (en) 1998-03-19
ATE236654T1 (de) 2003-04-15
WO1998008546A8 (en) 2001-04-19
EP0928200B1 (en) 2003-04-09

Similar Documents

Publication Publication Date Title
US6653322B1 (en) Therapeutic combinations of RAR antagonists and RXR agonists and use thereof
WO1998008546A9 (en) Therapeutic combinations of rar antagonists and rxr agonists and use thereof
Ross et al. Retinoids in embryonal development
JP4121552B2 (ja) レチノイン酸受容体アゴニストによる網膜色素上皮の増殖の阻止方法
US20070054961A1 (en) Factor
US20090093546A1 (en) Method and Pharmaceutical Compositions for Treatment of Anti-Estrogen Resistant Breast Cancer Using RXR Modulators
US6184256B1 (en) Methods and compositions for use in modulating expression of matrix metalloproteinase genes
JP2002542268A (ja) 過増殖性疾患の処置組成物および方法
Boettger-Tong et al. Cultured human uterine smooth muscle cells are retinoid responsive
US6713515B2 (en) Retinoic acid receptor antagonists as promoters of angiogenesis
US20060009520A1 (en) Retinoid-based methods for altering macrophage cholesterol
Kuriyan et al. Electrophilic PPARγ ligands inhibit corneal fibroblast to myofibroblast differentiation in vitro: a potentially novel therapy for corneal scarring
US6624154B1 (en) Compositions and methods for treatment of hyperproliferative diseases
US20020090352A1 (en) Compositions and methods for use in modulating immune system function
Bossenbroek et al. Expression of nuclear retinoic acid receptor and retinoid X receptor mRNA in the cornea and conjunctiva
Huang et al. Changes in the expression and subcellular localization of RARα in the rat hippocampus during postnatal development
MXPA99001757A (en) Therapeutic combinations of rar antagonists and rxr agonists and use thereof
JP3824422B2 (ja) レチノイン酸の活性増強剤
CA2209303C (en) Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
Sporn et al. Transforming Growth Factor ẞ
SOPRANO et al. Retinoid signaling.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040820

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040820

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070911

A313 Final decision of rejection without a dissenting response from the applicant

Free format text: JAPANESE INTERMEDIATE CODE: A313

Effective date: 20080130

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090407